- In the STEP 1 extension, participants who had lost a mean 17.3% of body weight on semaglutide 2.4 mg regained 11.6 percentage points of that loss during the 52 weeks after withdrawal, roughly two thirds of the weight they had lost.
- In STEP 4, people switched to placebo after a 20-week run-in gained 6.9% of body weight over the next 48 weeks, while those who continued semaglutide lost a further 7.9%.
- In SURMOUNT-4, participants switched to placebo after a 36-week tirzepatide lead-in regained 14.0% of body weight from week 36 to week 88, compared with a further 5.5% loss in those who continued.
- Improvements in blood pressure, HbA1c, lipids and inflammatory markers largely moved back toward pre-treatment values once the medication was withdrawn, in parallel with the weight.
- A 2026 meta-regression of six randomized trials estimated that about 60% of the weight lost during treatment was regained within one year of stopping, with modelled regain levelling off near 75% of the original loss.
- Proposed explanations include the return of appetite as drug levels fall, and the biological adaptations that follow any substantial weight loss, including persistent changes in appetite-regulating hormones.
- No published trial has established whether a reduced-intensity maintenance strategy, a defined treatment duration or a structured behavioral program can prevent this regain. This article is educational and contains no recommendation: every decision about starting, changing or stopping a prescribed medication belongs to you and your prescribing physician.
What happens to body weight after a GLP-1 receptor agonist is stopped?
The short answer from the published trials is consistent: when a GLP-1 receptor agonist is withdrawn, body weight rises again, the rise starts within weeks, and most of the weight lost during treatment returns over the following year. This has now been measured in three separate randomized programs (the STEP 1 trial extension, STEP 4 and SURMOUNT-4) using different medications, different treatment durations and different designs, and all three point the same way.
The magnitudes are not small. One year after semaglutide 2.4 mg was stopped, participants in the STEP 1 extension had regained about two thirds of the weight they had lost, leaving a mean net reduction of 5.6% from their original baseline rather than the 17.3% they had reached on treatment. In SURMOUNT-4, participants switched from tirzepatide to placebo gained 14.0% of body weight over 52 weeks, while those who stayed on treatment lost an additional 5.5% over the same period.
Two details are worth separating out, because they are often blurred. First, regain is partial, not total: in these trials the average participant one year after withdrawal still weighed less than at the very start, but considerably more than at the end of treatment. Second, the trajectory is not linear. The steepest part of the regain curve occurs in the first months after the last injection, then flattens.
This page deals only with what the evidence shows after treatment stops. It is not medical advice, it does not propose any way to prevent or manage regain, and it contains no suggestion to begin, alter, interrupt or resume any medication. Those decisions rest entirely with the prescribing physician, who can weigh an individual history, comorbidities and reasons for stopping in a way that no article can.
Which trials actually tested stopping a GLP-1 receptor agonist?
Three published studies form the backbone of the withdrawal evidence, and each answers a slightly different question.
The STEP 1 trial extension (Wilding et al., Diabetes, Obesity and Metabolism, 2022) followed a representative subset of participants who had completed the full 68 weeks of the original STEP 1 trial of semaglutide 2.4 mg or placebo, then observed them for a further 52 weeks with no study medication and, importantly, without the active lifestyle intervention support they had received during the trial. Extension analyses included 327 participants and were all exploratory, meaning they were not pre-specified hypothesis tests.
STEP 4 (Rubino et al., JAMA, 2021) was a randomized withdrawal trial. All participants first completed a 20-week open-label run-in (16 weeks of escalation plus 4 weeks at 2.4 mg weekly). The 803 participants who reached and tolerated the full weekly amount, 89.0% of those who started, were then randomized either to continue semaglutide (n = 535) or to switch to placebo (n = 268) for 48 weeks, with lifestyle intervention continuing in both arms.
SURMOUNT-4 (Aronne et al., JAMA, 2024) applied the same logic to tirzepatide. After a 36-week open-label lead-in at the maximum tolerated amount (10 or 15 mg weekly), during which the 670 participants achieved a mean weight reduction of 20.9%, they were randomized to continue tirzepatide or switch to placebo for 52 more weeks. Mean age was 48 years, 71% were women, and mean baseline weight was 107.3 kg.
The distinction between these designs matters. STEP 4 and SURMOUNT-4 are blinded randomized withdrawal trials, so the comparison between continuing and stopping is internally controlled. The STEP 1 extension is an uncontrolled observational follow-up of people who all stopped, which captures something closer to a complete discontinuation of both drug and structured support, but with weaker inferential strength.
How much weight returns, and how fast does it come back?
The three trials give convergent figures. In the STEP 1 extension, mean weight change from week 0 to week 68 had been 17.3% (SD 9.3) with semaglutide and 2.0% (SD 6.1) with placebo. By week 120, that is one year after withdrawal, the former semaglutide group had regained 11.6 percentage points (SD 7.7) of lost weight and the former placebo group 1.9 percentage points (SD 4.8). Net change from the original baseline was 5.6% for semaglutide and 0.1% for placebo.
In STEP 4, mean body weight change from week 20 to week 68 was minus 7.9% in those who continued semaglutide versus plus 6.9% in those switched to placebo, a difference of 14.8 percentage points (95% CI, minus 16.0 to minus 13.5; P < .001). In SURMOUNT-4, the equivalent figures from week 36 to week 88 were minus 5.5% with continued tirzepatide versus plus 14.0% with placebo, a difference of 19.4 percentage points (95% CI, minus 21.2 to minus 17.7; P < .001). Across the full 88 weeks, mean reduction from baseline was 25.3% with tirzepatide and 9.9% with placebo. Put differently, 89.5% of those continuing tirzepatide maintained at least 80% of their lead-in weight loss at week 88, compared with 16.6% of those switched to placebo.
Pooled analyses have tried to describe the shape of the curve rather than just its endpoint. A 2025 systematic review and meta-analysis of randomized trials (Tzang et al., eClinicalMedicine) reported a mean body weight increase of 5.63 kg (95% CI, 3.52 to 7.73) after GLP-1 receptor agonist discontinuation in people with obesity, alongside an HbA1c rise of 0.25%. A 2026 nonlinear meta-regression of six randomized trials totalling 3,236 participants (Budini, Luo et al., eClinicalMedicine) fitted an exponential recovery model and estimated that 60% of the weight lost during treatment was regained by one year after cessation, with the curve extrapolated to plateau at 75.3% (95% CI, 68.9 to 81.6) of the original loss.
That plateau figure is a model projection beyond the observed 52 weeks, not measured data, and should be read as such. What the observed data do support is a decelerating pattern: fastest regain early, slower later, with a residual difference from baseline still present at the end of follow-up.
What happens to blood pressure, HbA1c and lipids after withdrawal?
Weight is the headline, but the withdrawal trials also tracked cardiometabolic risk factors, and the pattern there mirrors the weight curve. The STEP 1 extension authors reported that the cardiometabolic improvements seen from week 0 to week 68 with semaglutide reverted toward baseline at week 120 for most variables, with changes that ended up similar to those in the placebo group. In other words, the improvements observed during treatment were not retained once weight came back.
The pooled evidence is consistent. The 2025 meta-analysis found a mean HbA1c increase of 0.25% after discontinuation, which is the kind of movement expected when both the direct glycemic effect of the medication and the indirect effect of lower body weight are removed at once. The 2026 meta-regression examined HbA1c and systolic blood pressure as secondary outcomes and described a similar early loss of the gains made on treatment, on a timescale of weeks rather than months.
There is a nuance that the trials do not fully resolve. Some of the post-withdrawal change in markers is attributable to the weight returning, and some to the loss of the medication's own direct actions on glucose handling, gastric emptying and insulin secretion. Because weight and drug exposure change together at withdrawal, the published analyses cannot cleanly separate the two contributions.
Gastrointestinal effects run in the opposite direction after stopping. In STEP 4, gastrointestinal adverse events were reported by 49.1% of participants continuing semaglutide versus 26.1% of those switched to placebo, and discontinuation for adverse events was similar in the two arms (2.4% versus 2.2%). The tolerability profile during treatment is covered separately in our overview of GLP-1 side effects.
Why does weight come back after the medication is withdrawn?
Two explanatory threads appear in the literature, and they are not mutually exclusive.
The first is pharmacological and fairly straightforward. These molecules act on GLP-1 receptors in hypothalamic and brainstem circuits that regulate appetite, satiety and food reward, and tirzepatide adds GIP receptor activity. Both are long-acting peptides engineered for weekly administration, with elimination half-lives on the order of several days to about a week, so plasma concentrations fall over roughly a month after the final injection. As exposure declines, the appetite suppression it produced declines with it, energy intake drifts upward, and weight follows. On this reading, the medication was managing an ongoing condition rather than resetting it, which is how the STEP 1 extension authors framed their own findings when they concluded that continued treatment is required to maintain improvements in weight and health.
The second thread concerns adaptations to weight loss itself, independent of how the loss was achieved. Sumithran and colleagues (New England Journal of Medicine, 2011) followed 50 adults with overweight or obesity through a 10-week very-low-energy diet and measured appetite-regulating hormones at baseline, at 10 weeks and at 62 weeks. A year later, several of those hormonal changes had not returned to pre-weight-loss values, a pattern the authors linked to the tendency to regain. Reduced resting energy expenditure after weight loss, often described as metabolic adaptation, is discussed in the same literature. If these adaptations persist, then anyone who has lost a large amount of weight faces biological pressure toward regain once the intervention that suppressed appetite is removed.
It is worth being explicit about the status of this second mechanism in the GLP-1 withdrawal trials specifically: the STEP and SURMOUNT withdrawal studies measured weight and cardiometabolic markers, not energy expenditure or appetite hormones. The mechanistic account is therefore borrowed from adjacent research and remains a proposed explanation rather than something these trials demonstrated.
How does the after-stopping picture differ from the treatment phase?
The withdrawal data are easy to misread if they are mixed with the on-treatment data, because the two phases answer different questions.
During treatment, the published trials describe a progressive loss that continues for roughly 60 to 72 weeks before flattening, with mean reductions in the region of 15% to 17% of body weight for semaglutide 2.4 mg in STEP 1 and around 21% to 25% for tirzepatide at the maximum tolerated amount in SURMOUNT-4. If what you are looking for is that on-treatment trajectory, week by week, it is set out in our semaglutide results timeline and our tirzepatide results timeline. Those pages cover the period while the medication is being taken.
After withdrawal, the curve inverts. The direction of change reverses within weeks, and the rate of regain in the first months is of a similar order of magnitude to the rate of loss that had been observed during the escalation phase. What does not reverse, at least within the one-year follow-up windows published so far, is the whole of the loss: mean weight at the end of follow-up remained below the original baseline in all three programs.
One further asymmetry deserves mention. In STEP 4 and SURMOUNT-4, the placebo arms continued to receive the trial's lifestyle intervention and still regained substantially. In the STEP 1 extension, structured lifestyle support ended along with the medication. The regain observed in those randomized withdrawal arms therefore cannot be attributed simply to the loss of behavioral support, since that support was still in place.
How do trial withdrawals compare with stopping outside a trial?
Trial withdrawal is a planned, blinded, fully documented event. Stopping outside a trial usually is not, and the observational literature suggests it is common. A retrospective cohort of 125,474 US adults with overweight or obesity who newly started liraglutide, semaglutide or tirzepatide between 2018 and 2023 (Rodriguez et al., JAMA Network Open, 2025) found that 64.8% of those without type 2 diabetes had discontinued within one year, compared with 46.5% of those with type 2 diabetes. Among those who discontinued, reinitiation within a year was 36.3% in people without type 2 diabetes and 47.3% in those with it.
Those are utilization data, not outcome data, and the authors noted that electronic health records may not capture every reason for stopping. Cost, coverage, supply interruptions, tolerability and personal choice are all bundled together in a single discontinuation event. The cohort period also overlapped years of well-documented supply constraints, which the analysis did not adjust for.
Still, the juxtaposition is informative. The randomized trials describe what happens to weight when the medication is removed under controlled conditions; the cohort data suggest that removal happens frequently in practice. The same study reported that each additional 1% of weight regained after stopping was associated with a modestly higher likelihood of restarting, about 2.3% in people with type 2 diabetes and 2.8% in those without, which is one of the few quantitative links published between post-withdrawal regain and subsequent behavior.
What none of this tells you is what any individual should do. Reasons for stopping differ enormously, from side effects to pregnancy planning to access, and the appropriate response differs with them. That evaluation is a clinical one.
What are the limits of the withdrawal evidence?
Several limitations constrain how far these results can be pushed.
Follow-up is short. The longest published off-treatment windows run about one year (52 weeks in the STEP 1 extension, 48 to 52 weeks in the randomized withdrawal arms). Everything said about where the regain curve settles after that point is extrapolation, including the 75.3% plateau estimate from the 2026 meta-regression.
The STEP 1 extension was exploratory and partial. Only a subset of trial completers entered the extension, 327 participants were analyzed, and the authors stated that all extension analyses were exploratory. Subset follow-up invites selection effects, since the people willing to be followed for another year are not necessarily representative.
Populations were narrow. STEP 1 and SURMOUNT-4 enrolled adults with obesity or overweight without type 2 diabetes, and participants were predominantly women and, in SURMOUNT-4, 80.1% White. Results cannot be assumed to transfer unchanged to people with type 2 diabetes, to adolescents, to older adults with sarcopenia, or to populations not represented in the samples.
Body composition was not the focus. The withdrawal publications report body weight, waist circumference and standard cardiometabolic markers. They are not designed to characterize what proportion of regained weight is fat versus lean mass, nor whether the composition of regained weight differs from the composition of what was lost. That is a real gap, and claims about it that cite these trials are overreaching.
All three programs were industry-sponsored (STEP 1 and STEP 4 by Novo Nordisk, SURMOUNT-4 by Eli Lilly), which is normal for registration programs but is part of a complete reading of the evidence. The randomized, blinded design of the withdrawal phases is the main structural protection against sponsor effects on the primary comparison.
What remains unknown about maintenance after treatment ends?
The withdrawal trials answered a narrow question well: what happens when the medication is replaced by placebo. They left several larger questions open.
Whether a reduced-intensity maintenance approach changes the trajectory is unknown. STEP 4 and SURMOUNT-4 compared full continuation against complete withdrawal. Neither tested an intermediate strategy, and the SURMOUNT-4 investigators said as much, noting that it is not certain whether a lower amount of medication, a more intensive behavioral program or some other approach would support maintenance. No published randomized trial has settled this, so any specific maintenance scheme discussed online is at present an untested hypothesis rather than an evidence-based strategy.
Whether there is a treatment duration after which weight is held is unknown. The STEP 1 extension followed people who had been treated for 68 weeks and SURMOUNT-4 for 36 weeks before randomization, and regain occurred in both. A 2025 narrative review of randomized withdrawal studies (Quarenghi et al., Journal of Clinical Medicine) concluded that rapid regain followed cessation regardless of how long treatment had lasted. Whether multi-year exposure behaves differently has not been tested.
Whether individual predictors exist is unknown. The standard deviations in the STEP 1 extension (SD 7.7 percentage points for regain) show wide variation between individuals around the mean. Some participants regained far less than two thirds of their loss and some far more. No validated predictor of who falls where has been published.
Longer-term cardiometabolic consequences are unknown. Markers reverted toward baseline within a year, but whether a period of substantial weight loss followed by regain leaves any durable benefit, or any durable harm, on hard clinical outcomes has not been measured in these cohorts.
This article is provided for educational purposes only and is not a substitute for medical advice, diagnosis or treatment. It deliberately contains no recommended amounts, no schedules and no protocols. If you are taking, considering or thinking about stopping a GLP-1 receptor agonist, discuss it with the physician who prescribes it.
Frequently Asked Questions
Does all the weight come back after stopping a GLP-1 receptor agonist?
How soon after the last injection does weight start to rise?
What was the difference between STEP 4 and the STEP 1 extension?
Did SURMOUNT-4 find the same pattern with tirzepatide?
Do blood pressure and blood sugar improvements persist after stopping?
Why does appetite seem to return so strongly after withdrawal?
Is there evidence that a lighter maintenance approach prevents the regain?
How many people stop these medications outside of a trial?
Recommended products
Research peptides selected for quality and purity:
GHK-Cu
Anti-Aging Compound
GHK-Cu Pen
Pre-filled Pen GHK-Cu
GLOW-UP Ritual
3-pen pack: Glow, NAD+, GHK-Cu
Test your knowledge
Quick quiz · 6 questions
Sources
- Wilding JPH, Batterham RL, Davies M, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism (PMID 35441470). (PubMed)
- Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14) (PMID 33755728). (PubMed)
- Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1):38-48 (PMID 38078870). (PubMed)
- Tzang CC, Wu PH, Luo CA, et al. (2025). Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. eClinicalMedicine, 90:103680 (PMID 41399474). (PubMed)
- Budini B, Luo S, et al. (2026). Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. eClinicalMedicine. (thelancet.com)
- Sumithran P, Prendergast LA, Delbridge E, et al. (2011). Long-Term Persistence of Hormonal Adaptations to Weight Loss. New England Journal of Medicine, 365(17):1597-1604 (PMID 22029981). (PubMed)
- Rodriguez PJ, Zhang V, Gratzl S, et al. (2025). Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Network Open, 8(1):e2457349. (jamanetwork.com)
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 384(11):989-1002 (PMID 33567185). (PubMed)
- Quarenghi M, Capelli S, Galligani G, et al. (2025). Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies. Journal of Clinical Medicine, 14(11):3791. (mdpi.com)